Thus, understanding the molecular mechanisms involved in controlling ERα activity in tumour cells will not only be critical for the development of new markers for screening and early detection, but also for the identification of additional prognostic indicators for treatment design and novel targets for the development of more effective breast cancer therapies. This evidence concerns the gene ERAL1 and breast carcinoma.